Purpose of review Cerebral microbleeds (CMBs) are a radiological marker of cerebral small vessel disease corresponding to small haemosiderin foci identified by blood-sensitive MRI. CMBs are common in older community populations, and in individuals with ischaemic stroke or transient ischaemic attack (TIA), and intracerebral haemorrhage (ICH). We summarize how CMBs might contribute to assessing the future risk of ischaemic stroke and ICH to inform antithrombotic (antiplatelet or anticoagulant) decisions.
INTRODUCTION
Although cerebral microbleeds (CMBs) have been extensively investigated since their first description in 1996 [1] , important questions about underlying mechanisms and clinical relevance remain unanswered. CMBs are the radiological correlate of haemosiderin-laden macrophages resulting from small, usually chronic haemorrhages [2] [3] [4] . Interest has focussed on CMBs as a potential marker of a 'bleeding prone' small vessel arteriopathies, with potential to predict symptomatic intracerebral haemorrhage (ICH) risk [5, 6] . However, CMBs are also a risk factor for ischaemic stroke [7, 8] , possibly explained by alternative 'ischaemic' pathophysiological mechanisms [9] [10] [11] . Antithrombotic (antiplatelet and anticoagulant) use in patients with CMBs is a highly topical clinical dilemma [12] , which will become increasingly common with an aging population often investigated with MRI and exposed to antithrombotic drugs for stroke and cardiovascular prevention. The present review provides up-to-date information on the clinical relevance of CMBs for antithrombotic use.
DEFINITION, MECHANISMS AND POTENTIAL RELEVANCE OF CEREBRAL MICROBLEEDS FOR ANTITHROMBOTIC DECISIONS
CMBs are defined radiologically as small (generally <10 mm) ovoid or rounded black signal voids on paramagnetic-sensitive MRI sequences, including
T2
Ã gradient-recalled echo weighted and susceptibility-weighted imaging [13] . CMBs must be differentiated from 'mimics' [13] , and account taken of technical imaging aspects affecting detection [14] [15] [16] . Standardized rating scales or automated techniques can improve reliability of CMB rating [17] [18] [19] . Studies of the pathological correlates of CMBs include only 23 patients [4, 20 && ] mainly with ICH or dementia. Nevertheless, most observations suggest that CMBs are self-limiting regions of red cell extravasation from damaged small blood vessels. CMB location predicts the type of underlying small vessel disease: an arteriopathy associated with systemic arterial hypertension and pathological changes in small perforating arteries of the deep grey and white matter (often termed 'hypertensive arteriopathy') causes CMBs in deep (basal ganglia) as well as lobar regions. In Western (Caucasian) people with ICH, CMBs in a strictly lobar distribution are highly specific for cerebral amyloid angiopathy (CAA), which causes progressive deposition of amyloid-b in small cortical and leptomeningeal arterial walls [3] , although this pattern might not be so specific in Eastern (Asian) people and in those without ICH [21, 22] . Figure 1 shows the different radiological distributions of CMBs.
More recently, ischaemic mechanisms for CMBs have been identified: ischaemia-mediated iron store released by oligodendrocytes; [9] phagocytosis of red cell microemboli into the perivascular space (termed angiophagy); [10] and haemorrhagic transformation of microinfarcts [11] , which might contribute to the clinical associations between CMBs and future ischaemic stroke risk.
CMBs might be relevant for ICH risk with antithrombotic exposure: first, CMBs are common in populations likely to be exposed to antithrombotic drugs, including older community-dwelling individuals and those with ischaemic stroke, transient ischaemic attack (TIA) or ICH [23 && ]; and second, longitudinal studies confirm that CMBs dynamically develop over time after ischaemic stroke, TIA or ICH [24, 25] (although regression of CMBs can occur, it seems to be rare). Because antithrombotics impair haemostasis by inhibiting platelet aggregation (antiplatelets) or disrupting the coagulation pathway (anticoagulants), in the presence of a CMB-related arteriopathy, normally self-limiting red blood cell extravasation (causing a CMB) could become a symptomatic ICH (Fig. 2) .
CURRENT EVIDENCE ON CLINICAL OUTCOMES FOLLOWING ANTITHROMBOTIC USE IN DIFFERENT POPULATIONS EVALUATED FOR CEREBRAL MICROBLEEDS
When CMBs are detected in a patient with a risk of future ischaemic vaso-occlusive disease, should
KEY POINTS
CMBs can be because of both haemorrhagic and ischaemic mechanisms, and are associated with an increased risk of both ischaemic stroke and ICH in all populations studied, including community-dwelling older adults, ischaemic stroke or TIA, and ICH.
CMBs should not currently influence antithrombotic decisions in nonstroke (community-dwelling) populations.
In ischaemic stroke or TIA populations, a small number of CMBs (<5) is associated with a higher risk of recurrent ischaemic stroke than ICH, so should not routinely influence antithrombotic decisions.
In patients with ischaemic stroke or TIA treated with antithrombotics, an increasing burden (number) of CMBs is associated with a steep increase in ICH risk: individuals with a high CMB burden (>5) have similar absolute risks of ICH and recurrent ischaemic stroke, so that antithrombotic use might cause net harm.
CMBs and other haemorrhagic imaging markers (e.g. cortical superficial siderosis) are associated with a substantial risk of recurrent CAA-related ICH, and current limited evidence suggests that avoiding antithrombotics is probably appropriate in individuals with this high-risk profile. antithrombotic drugs be recommended? Without randomized trial data, the best evidence is from prospective observational cohorts and pooled meta-analyses. We suggest considering: the population (nonstroke, ischaemic stroke/TIA, or ICH); the type of antithrombotic (antiplatelet or anticoagulant); the overall risk of ischaemic stroke and ICH; CMB presence, burden and distribution; the balance of future ischaemic stroke and ICH; and judgement of the likely net benefit and harm of antithrombotic treatment (Table 1) .
NONSTROKE (OLDER COMMUNITY) POPULATIONS
The diagnostic accuracy of a strictly lobar CMB pattern for CAA seems limited in non-ICH (community) cohorts. In a recent study, strictly lobar CMBs had a positive predictive value for pathology-proven CAA of only 25% [32 & ], although participants had very few CMBs [33] . Longitudinal studies of outcome related to CMBs in community cohorts are shown in Table 1 . In the Rotterdam study [23 && ], of 4759 participants aged at least 45 years with mean follow-up of 4.9 years, CMBs were associated with an increased risk of all stroke [hazard ratio 1.93; 95% confidence interval (CI), 1.25-2.99]; this was lower (and not statistically significant) for ischaemic stroke (hazard ratio 1.52; 95% CI, 0.91-2.53) than for ICH (hazard ratio 5.64; 95% CI, 1.66-19.53). Nonstrictly lobar CMBs (i.e. non-CAA pattern) were associated with an increased the risk of both ischaemic stroke and ICH whereas strictly lobar CMBs (indicating probable CAA) were associated only with ICH risk. Six participants with multiple CMBs developed a first-ever ICH during follow-up; three had used antithrombotic agents (either platelet inhibitors or oral anticoagulants). However, the overall stroke risk associated with CMBs was not affected by the use of antithrombotics. Preexisting CMBs were associated with lacunar infarction whereas incident lobar CMBs are associated with progression of white matter lesions, suggesting shared ischaemic mechanisms.
A large Japanese population-based study showed that CMB presence was associated with both ischaemic stroke (hazard ratio 4.48; 95% CI, 2.20-12.2) and ICH (hazard ratio 50.2; 95% CI, 16.7-150.9) [26] , but did not explore CMB burden, topography or associations with antithrombotics. A hospitalbased study in patients with incidental lobar CMBs without stroke reported ICH rates comparable to CAA-associated ICH [31] and that warfarin was an independent risk factor for ICH (P ¼ 0.02). However, this population had a median of 10 lobar CMBs, suggesting severe CAA, so these findings cannot be generalized to other stroke-free populations with incidentally found CMBs.
In summary, in community-dwelling populations, there is no clear evidence that the benefits of ischaemic stroke prevention by the use of antithrombotic drugs outweigh the risk of ICH in people with CMBs. Further interventional controlled 
ISCHAEMIC STROKE AND TIA POPULATIONS
The clinical relevance of CMBs is perhaps most uncertain in the ischaemic stroke and TIA population, because standard care includes antithrombotics for stroke secondary prevention. Does any increased risk of ICH in patients with CMBs outweigh the benefit in reducted future ischaemic stroke risk associated with antithrombotic therapy? Although risk instruments can be used to assess overall future ischaemic stroke risk in atrial fibrillation (AF) (e.g. CHA 2 DS 2 VASC) or after TIA (ABCD2), as well as overall bleeding risk in AF (e.g. HAS-BLED), there are currently very limited data on how CMBs and other brain imaging findings might help personalise antithrombotic therapy to maximize benefit and minimize risk.
In recent studies, antiplatelets [34] [35] [36] and anticoagulants [36, 37] are associated with the presence of CMBs and the development of new CMBs over time. However, establishing the clinical relevance of CMBs requires key clinical outcomes, including recurrent stroke. A recent aggregate data metaanalysis from 15 studies of patients with ischaemic stroke or TIA including 5068 patients over a median of 18 months follow-up showed that baseline CMBs are associated with an increased risk of both ischaemic stroke (pooled RR 1.8; 95% CI, 1.4-2.5) and ICH (pooled RR 6.3; 95% CI, 3.5-11.4) [27 && ]. The risk ratio for both ischaemic stroke and ICH increased with CMB burden, but more steeply for ICH than IS: in individuals with more than five CMBs the RR of ischaemic stroke was 2.7, while that of ICH was 14.1 ( Fig. 3) . At all CMB counts, the absolute risk of ischaemic stroke exceeded that of ICH, although in those with more than five CMBs, the absolute risk of ICH (8.8%) approached that of ischaemic stroke (10.5%). In randomized trials, antiplatelet agents only modestly reduce the absolute risk of ischemic stroke (0.5-2.5%) [38] , whereas the recent meta-analysis showed that at least five CMB are associated with an absolute risk increase of 8.2% for ICH and 5.1% for ischaemic stroke. Because ICH is generally more severe than ischaemic stroke, it is possible that in individuals with more than five CMBs, antithrombotic treatment may be associated with net harm. The prevalence of patients with at least five CMBs ranged from 12 to 51% [27 && ], suggesting this dilemma will be encountered often in clinical practice. However, because most individuals in this meta-analysis were treated with antithrombotic drugs (79% with antiplatelets, 15% with anticoagulants), it cannot be concluded that CMBs should be avoided in patients with more than five CMBs. The benefit of antithrombotics in patients with ischaemic stroke/TIA with many (e.g. >5) CMBs will only be determined by randomized controlled trials. Nevertheless, these data do provide reassurance that in individuals with ischaemic stroke or TIA and less than five CMBs, there is no suggestion that antithrombotics are hazardous, so should be used according to current care guidelines.
Data on the association between CMBs and stroke risk on patients with ischaemic stroke or TIA treated with anticoagulants are extremely limited. A small study in 134 patients with TIA or ischaemic stroke associated with AF (65% treated with anticoagulants) over a median follow-up of 2.4 years [39] found that CMBs were associated with an increased unadjusted risk of all stroke (21 vs. 9%, P ¼ 0.06) but there was only one ICH. A study from Korea in 504 patients with ischaemic stroke or TIA (97% discharged on anticoagulation) [29] found that strictly lobar CMBs were associated with ICH mortality (hazard ratio 5.91; 95% CI, 1.58-22.11) whilst increasing CMB burden was associated with all cause (hazard ratio 1.99; 95% CI, 1.03-3.85) and ischaemic stroke mortality (hazard ratio 3.39; 95% CI, 1.39-8.28) but did not report on nonfatal ischaemic stroke or ICH. A retrospective study from the same Korean group including 550 ischaemic stroke patients with AF (83% discharged on anticoagulation) found that higher CHADS2 and CHA(2) DS(2)VASC scores were associated with the presence and number of CMBs. Recurrent ICH was associated with CMB presence (hazard ratio 3.79; 95% CI, 1.09-13.15) but not CHADS2 or CHA(2)DS(2)VASC FIGURE 3. Risk ratio of both ischaemic stroke and intracerebral haemorrhage depending on CMB burden in patients with ischaemic stroke or TIA. CMB, cerebral microbleeds; ICH, intracerebral haemorrhage; IS, ischaemic stroke; TIA, transient ischaemic attack.
scores; recurrent ischaemic stroke risk was not reported [40] . A small prospective single centre study from Japan followed 119 patients with AF (86% anticoagulated) for a median of 17 months [41] ; CMBs were not associated with recurrent stroke (both ICH and ischaemic stroke), but because of the small number of events ischaemic stroke and ICH risk could not be examined separately.
There is thus an urgent need for more large-scale data on how CMBs might affect the balance of ischaemic stroke and ICH in patients with ischaemic stroke/ TIA treated with oral anticoagulants. Two large multicentre inception cohort studies will help to address this gap: Clinical Relevance of Microbleeds in Stroke (CROMIS 2; see https://www.ucl.ac.uk/cromis-2, https://clinicaltrials.gov/ct2/show/NCT02513316) [42] and Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance (HERO; see http://heropub.pic.es, https://clinicaltrials.gov/ct2/show/NCT02238470).
INTRACEREBRAL HAEMORRHAGE POPULATIONS
The most feared, often lethal, complication of antithrombotic therapy is ICH. Recurrent ICH risk varies according to the location of the initial ICH: the annual ICH recurrence risk after deep (nonlobar, in the basal ganglia or brainstem) ICH is between 1.3 and 10.6% compared with 2.5 and 28.2% after lobar ICH [43] . Although deep ICH is attributed to hypertensive arteriopathy, lobar ICH may be because of either hypertensive arteriopathy or CAA. Cohort studies in CAA-related ICH or CMBs, diagnosed according to the Boston criteria, indicate a high recurrence rate of $10% per year [31]. The presence, burden and distribution of CMBs might increase the risk of recurrent ICH, and help to judge difficult antithrombotic decisions (Table 1) . In a study of 207 survivors of ICH followed for a median of 20 months, there were 39 recurrences of ICH [28] . CMB number was associated with recurrent ICH in patients with lobar but not deep ICH, whereas antiplatelet use did not affect the risk of recurrent ICH in either lobar (hazard ratio 0.8; 95% CI, 0.3-2.3, P ¼ 0.73) or deep location (hazard ratio 1.2; 95% CI, 0.1-14.3, P ¼ 0.88). By contrast, a small single-centre study in CAA-related ICH reported that aspirin was an independent risk factor for recurrent ICH (hazard ratio 3.95; 95% CI, 1.6-8.3, P ¼ 0.021) [30] .
Three other studies found that increasing CMB burden is associated with increasing ICH risk [5, 6, 30] , but none reported on ischaemic stroke risk. Two of these studies included only patients with lobar ICH, whilst the third included both deep and lobar ICH. The risk of ICH was particularly high with more than five CMBs (hazard ratio 4.12; 95% CI, 1.6-9.3 vs. no CMBs P ¼ 0.001) [30] with a 51% 3-year cumulative risk for more than five CMBs versus 14% 3-year cumulative risk for one CMB (P ¼ 0.003) [5] .
The use of anticoagulants following ICH thus presents a major clinical dilemma. The risk of ischaemic stroke without antithrombotic treatment must be weighed carefully against the possible increase in ICH risk associated with antithrombotic therapy. A decision analysis which modelled warfarin for AF in an ICH survivor suggested that in lobar ICH avoiding warfarin increased qualityadjusted life (QOL) years by 1.9, compared with 0.3 for deep ICH; the authors concluded that anticoagulation for AF should not be offered to patients with lobar ICH and only to survivors of deep ICH if the risk of ischaemic events was high (>7% per year) [44] . However, CMBs were not considered in this analysis. By contrast, recent real-world studies in large datasets from ICH survivors with AF suggest that anticoagulation reduces mortality and ischaemic complications, without an increase in ICH [45
& ], and also reduced hospitalization costs [47] . However, none of the real world studies stratified ICH by location, nor by CMB burden or distribution. Further studies in ICH cohorts phenotyped according to CAA diagnostic criteria, with assessment of interactions of CMB pattern and burden with antithrombotic use may help clarify this enduring clinical dilemma. Two ongoing randomized trials of antithrombotic use after ICH will also help guide clinicians in these decisions in future: APACHE-af (http://apache-af.nl -aspirin vs. apixaban vs. noantithrombotics for the treatment of AF in patients after ICH) and RESTART (www.restarttrial.org -antiplatelets vs. no antiplatelets in patients with ICH with an indication for antiplatelets).
OTHER IMAGING MARKERS
Other imaging markers of small vessel disease include cortical superficial siderosis (cSS), leukoaraiosis and enlarged perivascular spaces. cSS seems to be strongly associated with probable CAA [48, 49] and with increased recurrent ICH risk [49] [50] [51] , especially if disseminated [49] .
CONCLUSION
Cerebral microbleeds are a risk factor for both future ischaemic stroke and ICH in all populations studied, including healthy older people, and those with ischaemic stroke, TIA or ICH. Following ischaemic stroke or TIA treated with antithrombotics, increasing CMB burden increases the risk of ICH more steeply than that of ischaemic stroke; in patients with a large number of CMBs (e.g. >5) the risks of future ICH and ischaemic stroke are finely balanced, and antithrombotics might cause net harm. However, most of the evidence in ischaemic stroke and TIA cohorts is from patients treated with antiplatelet agents rather than anticoagulants. Large global collaborative networks will be needed to obtain the necessary data to assess any potential hazard of CMBs, especially associated with the use of in anticoagulants; the Microbleeds International Collaborative Network [52 & ] will undertake a systematic review and individual patient data meta-analysis of the clinical relevance of CMBs in patients with TIA and ischaemic stroke treated with antithrombotics (the prospectively registered protocol is published at: www.crd.york.ac.uk/PROS PERO/display_record.asp?ID=CRD42016036602).
ICH patients with probable CAA (i.e. those with lobar ICH and either strictly lobar CMBs or disseminated cortical superficial siderosis) have a high baseline annual risk of ICH (>5% per year), which is likely to be increased substantially with the use of anticoagulants. We suggest that these patients should usually avoid anticoagulation; if essential to prevent further ischaemic events (e.g. in the presence of high risk AF), nonvitamin K antagonists are preferable because of a lower risk of ICH [53] . Alternatives to anticoagulation for patients with AF include left atrial appendage occlusion [54] , which is as effective as oral anticoagulants but likely to have lower future ICH risk than long-term oral anticoagulation in ICH survivors. Figure 4 is a treatment algorithm suggested by the authors based on current evidence.
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